Double-Blind, Double Dummy, Randomized Comparison Study to Evaluate the Efficacy and Safety of Valdecoxib 10 mg Once Daily and Naproxen 500 mg Twice Daily in Treating the Signs and Symptoms of Osteoarthritis of the Knee

NCT00652808

Last updated date
Study Location
Pfizer Investigational Site
Anyang, , 431-070, Korea, Republic of
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Osteoarthritis, Knee
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Korean outpatients with symptomatic radiologic evidence of OA of the knee (diagnosed according to the modified American College Rheumatology criteria)

- Patient's Assessment of Arthritis Pain measurement of at least 40 mm on VAS

- Patients had not received any NSAIDs or analgesics within 2 days (within 4 days for subjects taking oxaprozin, piroxicam or full dose aspirin) prior to the Baseline Visit

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Diagnosis of inflammatory arthritis, gout, pseudogout, Paget's disease, or any chronic
pain syndrome that, in the Investigator's opinion, would interfere with the assessment
of the Index Knee


- Symptomatic anserine bursitis or acute joint trauma of the Index Knee


- Arthroscopy performed on the Index Knee within the past 12 months


- Complete loss of articular cartilage of the Index Knee


- Administration of oral, or intramuscular, intravenous, or soft tissue injections of
corticosterosteroids within 4 weeks prior to screening visit


- Administration of intra-articular injection of corticosteroids or hyaluronic acid
preparation in the Index Knee within 3 months or 6 months, respectively

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Osteoarthritis, KneeEfficacy and Safety of Celecoxib Versus Placebo in the Treatment of Patients With Osteoarthritis of the Knee Who Were Unresponsive to Naproxen and Ibuprofen
NCT00640627
  1. Phoenix, Arizona
  2. Tucson, Arizona
  3. Long Beach, California
  4. Paramount, California
  5. Tustin, California
  6. Colorado Springs, Colorado
  7. Wheat Ridge, Colorado
  8. DeLand, Florida
  9. Naples, Florida
  10. Pembroke Pines, Florida
  11. Saint Petersburg, Florida
  12. Woodstock, Georgia
  13. Overland Park, Kansas
  14. New Orleans, Louisiana
  15. Baltimore, Maryland
  16. Flowood, Mississippi
  17. Chesterfield, Missouri
  18. Reno, Nevada
  19. Albuquerque, New Mexico
  20. Mason, Ohio
  21. Beaver, Pennsylvania
  22. Camp Hill, Pennsylvania
  23. Jenkintown, Pennsylvania
  24. Greensboro, South Carolina
  25. Johnson City, Tennessee
  26. Murfreesboro, Tennessee
  27. Nashville, Tennessee
  28. Austin, Texas
  29. San Antonio, Texas
  30. Seattle, Washington
ALL GENDERS
40 Years+
years
MULTIPLE SITES
Osteoarthritis, KneeSafety and Efficacy of Celecoxib Versus Placebo in the Treatment of Knee Osteoarthritis in Patients Who Were Unresponsive to Naproxen and Ibuprofen
NCT00638807
  1. Birmingham, Alabama
  2. Buena Park, California
  3. Denver, Colorado
  4. Washington, District of Columbia
  5. Longwood, Florida
  6. Miami, Florida
  7. Zephyrhills, Florida
  8. Boise, Idaho
  9. Boise, Idaho
  10. Morton Grove, Illinois
  11. Wichita, Kansas
  12. Wichita, Kansas
  13. Wheaton, Maryland
  14. Springfield, Missouri
  15. Bozeman, Montana
  16. Trenton, New Jersey
  17. Binghamton, New York
  18. Brooklyn, New York
  19. New York, New York
  20. Cary, North Carolina
  21. Winston-Salem, North Carolina
  22. Bismarck, North Dakota
  23. Eugene, Oregon
  24. Portland, Oregon
  25. Duncansville, Pennsylvania
  26. Johnstown, Pennsylvania
  27. Warwick, Rhode Island
  28. Charleston, South Carolina
  29. New Tazewell, Tennessee
  30. San Antonio, Texas
  31. Arlington, Virginia
  32. Norfolk, Virginia
  33. Seattle, Washington
ALL GENDERS
40 Years+
years
MULTIPLE SITES
Osteoarthritis, KneeRandomized, Double-Blind, Placebo-Controlled, Phase 2 Study In Subjects With Osteoarthritic Pain Of The Knee
NCT00689273
  1. DeLand, Florida
  2. South Miami, Florida
  3. Overland Park, Kansas
  4. Madisonville, Kentucky
  5. Chesterfield, Missouri
  6. Creve Coeur, Missouri
  7. St. Peters, Missouri
  8. New York, New York
  9. Cincinnati, Ohio
  10. Warwick, Rhode Island
  11. San Antonio, Texas
  12. Arlington, Virginia
  13. Clarksburg, West Virginia
  14. Seoul,
  15. Seoul,
  16. Seoul,
  17. Seoul,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Double-Blind, Double Dummy, Randomized Comparison Study to Evaluate the Efficacy and Safety of Valdecoxib 10 mg Once Daily and Naproxen 500 mg Twice Daily in Treating the Signs and Symptoms of Osteoarthritis of the Knee
Official Title  ICMJE Double-Blind, Double Dummy, Randomized Comparison Study to Evaluate the Efficacy and Safety of Valdecoxib 10 mg QD and Naproxen 500 mg BID in Treating the Signs and Symptoms of Osteoarthritis of the Knee
Brief Summary This study was performed to demonstrate that treatment with valdecoxib 10 mg daily (QD) was at least as effective as with naproxen 500 mg twice daily (BID), a standard non-steroidal anti-inflammatory drug (NSAID), when taken for 6 weeks in Korean subjects with symptomatic osteoarthritis (OA) of the knee. Secondary objectives were to assess the overall safety and tolerability of valdecoxib 10 mg QD taken for 6 weeks in Korean subjects with symptomatic OA of the knee.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE
  • Osteoarthritis
  • Knee
Intervention  ICMJE
  • Drug: valdecoxib
    valdecoxib 10 mg tablet by mouth once daily for 6 weeks
  • Drug: naproxen
    naproxen 500 mg capsule by mouth twice daily for 6 weeks
Study Arms  ICMJE
  • Active Comparator: Arm 1
    Intervention: Drug: valdecoxib
  • Active Comparator: Arm 2
    Intervention: Drug: naproxen
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: April 3, 2008)
265
Original Actual Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE September 2004
Primary Completion Date Not Provided
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Korean outpatients with symptomatic radiologic evidence of OA of the knee (diagnosed according to the modified American College Rheumatology criteria)
  • Patient's Assessment of Arthritis Pain measurement of at least 40 mm on VAS
  • Patients had not received any NSAIDs or analgesics within 2 days (within 4 days for subjects taking oxaprozin, piroxicam or full dose aspirin) prior to the Baseline Visit

Exclusion Criteria:

  • Diagnosis of inflammatory arthritis, gout, pseudogout, Paget's disease, or any chronic pain syndrome that, in the Investigator's opinion, would interfere with the assessment of the Index Knee
  • Symptomatic anserine bursitis or acute joint trauma of the Index Knee
  • Arthroscopy performed on the Index Knee within the past 12 months
  • Complete loss of articular cartilage of the Index Knee
  • Administration of oral, or intramuscular, intravenous, or soft tissue injections of corticosterosteroids within 4 weeks prior to screening visit
  • Administration of intra-articular injection of corticosteroids or hyaluronic acid preparation in the Index Knee within 3 months or 6 months, respectively
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Korea, Republic of
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00652808
Other Study ID Numbers  ICMJE A3471045
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Director, Clinical Trial Disclosure Group, Pfizer, Inc.
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date April 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP